LOSURDO, AGNESE
LOSURDO, AGNESE
Universita' degli Studi di MILANO
Choosing treatment options for patients with relapsed/refractory multiple myeloma
2014 R. Castelli, N. Orofino, A. Losurdo, R. Gualtierotti, M. Cugno
Clinicopathological and immunohistochemical characteristics in male breast cancer: a retrospective case series
2015 G. Masci, M. Caruso, F. Caruso, P. Salvini, C. Carnaghi, L. Giordano, V. Miserocchi, A. Losurdo, M. Zuradelli, R. Torrisi, L. Di Tommaso, C. Tinterri, A. Testori, C.A. Garcia Etienne, W. Gatzemeier, A. Santoro
Current and Emerging Treatment Options for Patients with Relapsed Myeloma
2013 R. Castelli, R. Gualtierotti, N. Orofino, A. Losurdo, S. Gandolfi, M. Cugno
Highly specialized Breast Centers did not experience delay of care during COVID-19 pandemic in Italy: the Senonetwork experience
2022 A. Losurdo, A.V.E. Lisa, M. Tomatis, A. Ponti, S. Montemezzi, E. Bonzano, L. Fortunato
Immunotherapeutic early-phase clinical trials and malignant gliomas : A single-center experience and comprehensive immunophenotyping of circulating leukocytes
2021 M. Simonelli, P. Persico, A. Capucetti, C. Carenza, S. Franzese, E. Lorenzi, A. Dipasquale, A. Losurdo, L. Giordano, F. Pessina, P. Navarria, L. Politi, D. Mavilio, M. Locati, S. Della Bella, A. Santoro, R. Bonecchi
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET)
2021 C. Vernieri, F. Nichetti, L. Lalli, L. Moscetti, C.A. Giorgi, G. Griguolo, A. Marra, G. Randon, C.G. Rea, F. Ligorio, S. Scagnoli, C. De Angelis, C. Molinelli, A. Fabbri, E. Ferraro, D. Trapani, A. Milani, E. Agostinetto, O. Bernocchi, G. Catania, A. Vantaggiato, M. Palleschi, A. Moretti, D. Basile, M. Cinausero, A. Ajazi, L. Castagnoli, S. Lo Vullo, L. Gerratana, F. Puglisi, N. La Verde, G. Arpino, A. Rocca, M. Ciccarese, R. Pedersini, A. Fabi, D. Generali, A. Losurdo, F. Montemurro, G. Curigliano, L. Del Mastro, A. Michelotti, E. Cortesi, V. Guarneri, G. Pruneri, L. Mariani, F. de Braud
MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
2015 L. de Mattos-Arruda, G. Bottai, P.G. Nuciforo, L. di Tommaso, E. Giovannetti, V. Peg, A. Losurdo, J. Pérez-Garcia, G. Masci, F. Corsi, J. Cortés, J. Seoane, G.A. Calin, L. Santarpia
Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
2021 A. Darwich, A. Silvestri, M.-. Benmebarek, J. Mouries, B. Cadilha, A. Melacarne, L. Morelli, D. Supino, A. Taleb, H. Obeck, C. Sustmann, A. Losurdo, G. Masci, G. Curigliano, S. Kobold, G. Penna, M. Rescigno
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors
2023 E. Zattarin, D. Presti, L. Mariani, C. Sposetti, R. Leporati, A. Menichetti, C. Corti, C. Benvenuti, G. Fuca, R. Lobefaro, F. Ligorio, L. Provenzano, A. Vingiani, M. Del Vecchio, G. Griguolo, M. Sirico, O. Bernocchi, A. Marra, P. Zagami, E. Agostinetto, F. Jacobs, P. Di Mauro, A. Esposito, C.A. Giorgi, L. Lalli, L. Boldrini, P.P.B. Giacchetti, A.C. Schianca, V. Guarneri, R. Pedersini, A. Losurdo, A. Zambelli, D. Generali, C. Criscitiello, G. Curigliano, G. Pruneri, F. de Braud, M.V. Dieci, C. Vernieri
Safety of autologous fat grafting in breast cancer: a multicenter Italian study among 17 senonetwork breast units autologous fat grafting safety : a multicenter Italian retrospective study
2021 M. Klinger, A. Losurdo, A.V.E. Lisa, E. Morenghi, V. Vinci, F. Corsi, S. Albasini, M.C. Leonardi, B.A. Jereczek-Fossa, P. Veronesi, M. Rietjens, L. Fabiocchi, S. Santicchia, F. Klinger, A. Loreti, L. Fortunato, M.A. Bocchiotti, F.A. Nicolo, P. Stringhini, P.C. Parodi, E. Rampino, V. Guarneri, G. Pagura, E.D. Venezia, G. Meneghini, T. Kraljic, P. Persichetti, M. Barone, N. Vaia, I. Zerini, L. Grimaldi, M. Riccio, A. Aquinati, F. Bassetto, V. Vindigni, L. Ciuffreda, C. Tinterri, A. Santoro